UK MHRA approves new formulation of Amgen’s XGEVA
The UK MHRA has granted marketing authorisation for a new formulation of Amgen’s XGEVA to prevent serious bone-related complications.
The UK MHRA has granted marketing authorisation for a new formulation of Amgen’s XGEVA to prevent serious bone-related complications.
What's Your Reaction?
